DiabetesMar 15, 2026
Bydureon (exenatide extended-release) can drop HbA1c by roughly 1.3 to 1.6 percentage points with a single weekly injection. That's a meaningful reduction for adults with type 2 diabetes who aren't getting enough from diet, exercise, and oral medications. But here's the tension worth understanding: head-to-head data show it's slightly less potent on both blood sugar and weight than liraglutide or semaglutide, two GLP-1 receptor agonists that now dominate the conversation.
So where does that leave Bydureon? Still effective, still convenient, but no longer the frontrunner. Whether it makes sense for you depends on what you're prioritizing and what trade-offs you're willing to accept.
MetforminMar 15, 2026
Roughly 1 in 5 metformin products tested in large international surveys contained a probable carcinogen above safety limits. That sounds alarming, and it should be taken seriously. But here's the tension: the other 80% of tested batches met quality and safety standards, no adverse events have been definitively linked to the contaminated products, and abruptly stopping metformin creates its own set of risks for people managing diabetes. The real question isn't whether the recalls were justified (they were), but what you should actually do about it.
Between 2020 and 2022, over 281 extended-release metformin products were recalled in the US alone. The contaminant at the center of all of this is NDMA (N-nitrosodimethylamine), a substance classified as a probable carcinogen. Regulators worldwide set a strict daily limit of 96 nanograms, and a meaningful minority of products exceeded it.
DiabetesMar 15, 2026
A single patch the size of a postage stamp delivered semaglutide for an entire month in animal studies, mimicking four weekly injections from one 2×2 cm application. That is genuinely exciting. It is also, for now, entirely experimental. No GLP-1 patch is approved or commercially available for diabetes or obesity. Every current GLP-1 receptor agonist, including semaglutide, liraglutide, dulaglutide, and tirzepatide, reaches patients through injections or, in the case of oral semaglutide, a daily pill.
So if you have seen headlines about GLP-1 patches and wondered whether you should ask your doctor about one, the honest answer is: not yet. But the research pipeline is worth understanding, because it signals where treatment is headed.
InsulinMar 15, 2026
NPH insulin has an image problem. It is older, cloudier, and requires more hands-on effort than the long-acting analogs that dominate modern prescribing. Yet the research paints a more nuanced picture: in type 2 diabetes, real-world data show similar or even better A1c results with NPH compared to pricier alternatives, and no reduction in serious hypoglycemia with those newer insulins. At 2 to 10 times less cost, NPH remains a genuinely effective basal insulin for a large number of people. The catch is that it demands more from the person using it.
Understanding where NPH truly falls short, and where the gap with analogs barely matters, can help you have a more honest conversation with your provider about what belongs in your regimen.
InsulinMar 15, 2026
Insulin's side effect profile is narrower than many people assume. Large, long-term trials point to just three main concerns: low blood sugar, modest weight gain, and local skin reactions at injection sites. Fears about insulin causing cancer or heart disease? Not supported by high-quality trial data.
But "narrow" doesn't mean "trivial." Hypoglycemia hits roughly 20% of basal insulin users each year and is a frequent driver of hospitalizations among older adults. Knowing which side effects actually warrant your attention, and which ones you can largely stop worrying about, changes how you approach insulin therapy day to day.
DiabetesMar 15, 2026
Jardiance (empagliflozin) reliably shaves off about 2 to 3 kilograms in people with type 2 diabetes, roughly 3 to 4% of body weight over three to six months. That's consistent and measurable, but it puts Jardiance firmly in the "mild" weight loss category, well below the 10%-plus losses seen with GLP-1 medications like semaglutide. If you're taking Jardiance and noticing the scale drift downward, that's expected. If you're considering it primarily for weight loss, the research suggests you'd be disappointed.
Empagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor, a class of drug designed to manage type 2 diabetes, heart failure, and kidney disease. Weight loss is a real but secondary effect, more of a metabolic bonus than the main event.
DiabetesMar 15, 2026
If you're taking Zepbound (tirzepatide) for weight loss or diabetes, here's some reassuring news: true injection-site reactions are rare. In a pooled analysis of over 5,000 patients across seven phase 3 clinical trials, only 2.7% experienced any injection-site reaction at all, and every single case was mild and non-serious. Just 4 people out of 5,025 (that's 0.08%) stopped the medication because of reactions at the injection site.
So what should you actually focus on to have the smoothest experience? The research points to several practical strategies, and most of them have nothing to do with where you stick the needle.
DiabetesMar 15, 2026
If you have diabetes or prediabetes, you've probably seen a number called "eAG" on your lab results, sitting right next to your HbA1c. It looks helpful. It takes that somewhat abstract A1c percentage and converts it into the same units you see on your glucose meter or continuous glucose monitor (CGM). An A1c of 7%? That translates to roughly 154 mg/dL. Simple, right?
Not quite. Research shows that eAG is a useful educational shortcut, but it can be off by a meaningful amount for many individuals. For about 1 in 10 people, the gap between what eAG predicts and what their blood sugar actually averages is large enough to matter clinically. This article will help you understand what eAG is really telling you, when you can trust it, and when you should look beyond it.
MetforminMar 15, 2026
No clinical trial has ever compared morning versus evening metformin dosing for weight loss. Not one. The question sounds reasonable, but the research simply hasn't found that clock time matters. What does matter: your total daily dose, whether you can tolerate it, and how long you stick with it.
Metformin produces real but modest weight loss in people with overweight or obesity, roughly 0.5 BMI units, or about 2 to 3 percent of body weight, over three months or more at doses ranging from 500 to 2,550 mg per day. That's meaningful, but it's not dramatic, and trying to optimize the hour you swallow the pill won't change that math.
DiabetesMar 15, 2026
Lantus (insulin glargine U100) doesn't actually lower your HbA1c more than the older, cheaper insulin it was designed to replace. Compared to NPH insulin, Lantus achieves similar overall blood sugar control. Where it consistently wins is in reducing nocturnal and severe hypoglycemia, the kind of lows that wake you up at 3 a.m. shaking and sweating. That distinction matters more than many people realize, because fear of nighttime lows is one of the biggest barriers to getting insulin doses where they need to be.
The other thing worth knowing upfront: multiple biosimilar versions of Lantus now exist, and the clinical data show they are highly similar in how they work, how well they work, and how safe they are. The choice between Lantus and its copies increasingly comes down to cost, which device you prefer, and how your body responds individually.
Kidney HealthMar 15, 2026
A small, abnormal amount of albumin in your urine, too little for a standard dipstick to catch, can flag serious kidney and cardiovascular problems long before you feel a thing. This signal, called microalbuminuria, shows up in roughly 7% of the general population and in about 39% of people with type 2 diabetes. What makes it particularly worth paying attention to: it independently predicts heart attacks, strokes, and death across a wide range of people, including those who seem perfectly healthy.
But the story has gotten more complicated. Researchers now recognize that microalbuminuria doesn't always march in a straight line toward kidney failure, that risk actually starts climbing well below the "abnormal" cutoff, and that treating it aggressively can sometimes reverse it entirely.
DiabetesMar 15, 2026
Your A1C number tells you more than whether you "have diabetes." It's a window into your risk for heart attacks, kidney failure, amputations, and death. But here's what surprises most people: danger lurks at both ends of the scale. An A1C that's too high is obviously bad, but pushing it too low can be just as risky, especially as you get older or if you have other health conditions.
The bottom line from a meta-analysis of 74 studies: for people with diabetes, A1C levels consistently at 8% or above signal clear danger, with risk climbing steeply above 9%. But for older adults or those with kidney or heart disease, even levels below 6% can increase mortality. Your ideal target isn't a single number that works for everyone.
DiabetesMar 15, 2026
If you've been following the wave of weight loss medications like semaglutide and tirzepatide, retatrutide represents a significant leap forward. In clinical trials, people taking this weekly injection lost roughly 22 to 24 percent of their body weight in under a year. To put that in perspective, that's approaching the kind of weight loss typically seen after bariatric surgery, achieved with a once-weekly shot instead of an operating room.
Retatrutide works by activating three hormone receptors simultaneously, compared to one for semaglutide and two for tirzepatide. That triple action translates into benefits that go well beyond the number on the scale, including dramatic improvements in liver fat, blood sugar control, and early signs of kidney protection. This article will walk you through what the phase 2 trial data actually shows, how it stacks up against existing options, what side effects to expect, and what's still unknown before this drug could reach your pharmacy.
DiabetesMar 15, 2026
Retatrutide delivers some of the highest weight loss numbers seen in obesity drug trials, but that potency comes at a cost. Network meta-analyses comparing it against other GLP-1 and dual agonist drugs consistently rank retatrutide among the highest for overall adverse events, particularly gastrointestinal ones. The side effects are common, overwhelmingly gut-related, and clearly dose-dependent. Most are mild to moderate. But "common and mild" still matters when you're the one experiencing weeks of nausea during dose escalation.
Here's what the phase 2 trial data actually reveals about what taking this drug feels like, what's manageable, and what signals deserve closer attention.
DiabetesMar 14, 2026
Most basal insulins ask you to be precise. Same time every day, no exceptions. Tresiba (insulin degludec) breaks that pattern. In clinical studies, people injected it anywhere from 8 to 40 hours apart without losing blood sugar control or compromising safety. That kind of flexibility is rare for a basal insulin, and it comes alongside another practical benefit: lower rates of nocturnal and overall hypoglycemia compared to older options like glargine and detemir.
If you're managing type 1 or type 2 diabetes and your current basal insulin feels like a rigid obligation, Tresiba offers something worth understanding.
InsulinMar 14, 2026
Over one-third of U.S. nursing home residents with diabetes are managed on sliding scale insulin alone, a method that multiple medical societies have flagged as potentially inappropriate for long-term use. The core problem: sliding scale insulin only reacts to high blood sugar after it happens. It never prevents it. Expert reviews describe the result as a "roller coaster" glucose pattern, and the research consistently shows it leads to worse control and more hypoglycemia than alternatives.
Yet it persists. Understanding why, and when it might still make sense, matters if you or someone you care about is being managed this way in a hospital or nursing home.
DiabetesMar 13, 2026
Fiasp delivers roughly double the insulin exposure in the first 30 minutes compared to standard insulin aspart, and about 70 to 75 percent more glucose-lowering in that same early window. Those are striking pharmacology numbers. Yet when you zoom out to the metrics most people care about, like A1c and time in range, the clinical advantage shrinks to something much more modest. That gap between impressive speed and underwhelming overall results is the central story of Fiasp, and understanding it helps you figure out whether it's worth the switch.
Fiasp is not a new insulin molecule. It is the same insulin aspart with two added ingredients: niacinamide (a form of vitamin B3) to speed absorption, and L-arginine to keep the formulation stable. That simple tweak shifts the entire action profile earlier, not bigger.
DiabetesMar 13, 2026
Metformin can reduce the chance of prediabetes progressing to type 2 diabetes by roughly 25 to 30 percent. That sounds meaningful, and it is. But here's the tension: lifestyle changes like diet and exercise consistently outperform the drug, and many people with prediabetes never progress to diabetes at all. Some even revert to normal blood sugar on their own. So the real question isn't whether metformin works. It's whether it makes sense for you.
The answer depends heavily on your age, weight, blood sugar levels, and medical history. For a specific subset of people, metformin is a genuinely useful tool. For the rest, it may be an unnecessary medication for a problem that better habits can solve more effectively.
NutritionMar 13, 2026
Research pooling data from over 12.8 million people shows that higher adherence to Mediterranean-style eating significantly reduces your risk of dying from cardiovascular disease, developing type 2 diabetes, and even experiencing cognitive decline.
The morning meal is your first opportunity each day to tap into these benefits. This article will help you understand what actually counts as a Mediterranean breakfast, why it works at the biological level, and how to make it practical for your life.
Metabolic HealthMar 13, 2026
Diabetes is a chronic metabolic condition that affects how the body regulates blood sugar. While it is well-known for its potential to cause complications such as cardiovascular disease, kidney failure, nerve damage, and vision loss, fewer people are aware that diabetes can also contribute to disability. In medical and legal contexts, “disability” refers to a physical or mental impairment that substantially limits one or more major life activities. This can include mobility limitations, reduced vision, difficulty with self-care, or challenges in work performance.
Research shows that people with diabetes experience higher rates of disability compared to those without the disease. A large-scale 2025 analysis found that diabetes prevalence was 5.8% among adults without a disability, but 9.5% among those with milder disabilities and 18.3% among those with moderate to severe disabilities. The likelihood of disability increased with the number of functional limitations present.
